AstraZeneca Pharmaceuticals LP
NEWS
The group said that the Phase III trial of Ultomiris (ravulizumab) lacked efficacy when it was used on adults diagnosed with amyotrophic lateral sclerosis.
There was plenty of clinical trial updates last week. Here’s a look.
In India, only 8.3% of the population is fully vaccinated, while Sudan, Myanmar, and Ethiopia all have blank spaces beside their names in that category.
The clinical study compared Enhertu to Kadcyla in HER2+ metastatic breast cancer patients who previously received trastuzumab.
Sierra will have access to AZD5153, a potent and selective BRD4 BET inhibitor, to initiate a study that combines the said component with momelotinib for treating patients with myelofibrosis.
Seventeen years after buying global rights, AstraZeneca is finally announcing a win for the lupus community with an FDA approval for Saphnelo.
Topline results from a late-stage trial show Regeneron Pharmaceuticals and Sanofi’s Dupixent reduced itch in biologic-naiïve patients with chronic spontaneous urticaria.
As COVID-19 infections continue to increase in the U.S., the FDA has expanded the EUA for Eli Lilly’s monoclonal antibody to include treatment with or without remdesivir.
AstraZeneca said in an earnings announcement on Thursday it will seek authorization for its COVID-19 vaccine in the U.S. sometime in the second half of this year.
JOBS
IN THE PRESS